JP2014221064A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014221064A5 JP2014221064A5 JP2014137893A JP2014137893A JP2014221064A5 JP 2014221064 A5 JP2014221064 A5 JP 2014221064A5 JP 2014137893 A JP2014137893 A JP 2014137893A JP 2014137893 A JP2014137893 A JP 2014137893A JP 2014221064 A5 JP2014221064 A5 JP 2014221064A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- isolated
- functional fragment
- mesothelin
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000003735 Mesothelin Human genes 0.000 claims description 9
- 108090000015 Mesothelin Proteins 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 2
- 102100023123 Mucin-16 Human genes 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US437807P | 2007-11-26 | 2007-11-26 | |
| US61/004,378 | 2007-11-26 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010535269A Division JP5608091B2 (ja) | 2007-11-26 | 2008-11-19 | 抗メソセリン抗体およびその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018038254A Division JP6717869B2 (ja) | 2007-11-26 | 2018-03-05 | 抗メソセリン抗体およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014221064A JP2014221064A (ja) | 2014-11-27 |
| JP2014221064A5 true JP2014221064A5 (enExample) | 2016-03-31 |
Family
ID=40351874
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010535269A Expired - Fee Related JP5608091B2 (ja) | 2007-11-26 | 2008-11-19 | 抗メソセリン抗体およびその使用 |
| JP2014137893A Pending JP2014221064A (ja) | 2007-11-26 | 2014-07-03 | 抗メソセリン抗体およびその使用 |
| JP2018038254A Expired - Fee Related JP6717869B2 (ja) | 2007-11-26 | 2018-03-05 | 抗メソセリン抗体およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010535269A Expired - Fee Related JP5608091B2 (ja) | 2007-11-26 | 2008-11-19 | 抗メソセリン抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018038254A Expired - Fee Related JP6717869B2 (ja) | 2007-11-26 | 2018-03-05 | 抗メソセリン抗体およびその使用 |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US9023351B2 (enExample) |
| EP (3) | EP2215121B1 (enExample) |
| JP (3) | JP5608091B2 (enExample) |
| KR (1) | KR101559599B1 (enExample) |
| CN (2) | CN101952319B (enExample) |
| AU (1) | AU2008329221B2 (enExample) |
| BR (1) | BRPI0819909B8 (enExample) |
| CA (1) | CA2706529C (enExample) |
| CO (1) | CO6280409A2 (enExample) |
| CR (1) | CR11456A (enExample) |
| CU (1) | CU23833A3 (enExample) |
| CY (1) | CY1117437T1 (enExample) |
| DK (1) | DK2215121T3 (enExample) |
| DO (1) | DOP2010000150A (enExample) |
| EC (1) | ECSP10010191A (enExample) |
| ES (1) | ES2569513T3 (enExample) |
| GT (1) | GT201000148A (enExample) |
| HN (1) | HN2010001062A (enExample) |
| HR (1) | HRP20160485T1 (enExample) |
| HU (1) | HUE027358T2 (enExample) |
| IL (1) | IL205681A0 (enExample) |
| MA (1) | MA31862B1 (enExample) |
| MX (1) | MX2010005603A (enExample) |
| MY (1) | MY157164A (enExample) |
| NZ (1) | NZ585551A (enExample) |
| PL (1) | PL2215121T3 (enExample) |
| SI (1) | SI2215121T1 (enExample) |
| TN (1) | TN2010000234A1 (enExample) |
| UA (1) | UA106036C2 (enExample) |
| WO (1) | WO2009068204A1 (enExample) |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2195017T1 (sl) * | 2007-10-01 | 2015-01-30 | Bristol-Myers Squibb Company | Človeška protitelesa, ki vežejo mezotelin in njihova uporaba |
| HUE027358T2 (en) * | 2007-11-26 | 2016-09-28 | Bayer Ip Gmbh | Anti-mesothelin antibodies and their applications |
| UY32560A (es) * | 2009-04-29 | 2010-11-30 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| PE20170917A1 (es) * | 2010-12-20 | 2017-07-12 | Genentech Inc | Anticuerpos anti-mesotelina e inmunoconjugados |
| US9402916B2 (en) | 2011-03-17 | 2016-08-02 | The University Of Birmingham | Re-directed immunotherapy |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| EP3501546A3 (de) | 2011-04-21 | 2019-09-18 | Seattle Genetics, Inc. | Cystein-wirkstoff konjugate und ihre verwendung |
| WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
| WO2014052064A1 (en) * | 2012-09-27 | 2014-04-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin antibodies and methods for eliciting potent antitumor activity |
| CN103819559B (zh) * | 2013-12-10 | 2016-02-24 | 中国科学院武汉病毒研究所 | 一种抗间皮素纳米抗体及其编码基因和该纳米抗体的用途 |
| CA2934617A1 (en) | 2013-12-23 | 2015-07-02 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with kinesin spindle protein (ksp) |
| NZ729808A (en) | 2014-09-30 | 2022-02-25 | Neurimmune Holding Ag | Human-derived anti-dipeptide repeats (dprs) antibody |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| BR112017024757A2 (pt) | 2015-05-18 | 2018-11-13 | TCR2 Therapeutics Inc. | composições e métodos para reprogramação de tcr utilizando proteínas de fusão |
| AU2016282723B2 (en) | 2015-06-22 | 2021-09-23 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzymatically cleavable groups |
| KR20180021136A (ko) * | 2015-06-30 | 2018-02-28 | 헨리우스 바이오테크 컴퍼니 리미티드 | 항-혈관 내피 성장 인자 수용체 2 (vegfr2) 항체 |
| KR20180055824A (ko) * | 2015-08-21 | 2018-05-25 | 카르스젠 테라퓨틱스 리미티드 | 항 메소텔린 완전 인간 항체 및 메소텔린을 타겟팅하는 면역효과 세포 |
| KR101782487B1 (ko) * | 2015-09-24 | 2017-09-27 | 재단법인 목암생명과학연구소 | 신규 항-메소텔린 항체 및 이를 포함하는 조성물 |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| PT3393504T (pt) | 2015-12-22 | 2025-12-30 | Novartis Ag | Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena |
| BR112018013074A2 (en) | 2015-12-30 | 2018-12-11 | Novartis Ag | immune effector cell therapies with enhanced efficacy |
| PL3418304T3 (pl) | 2016-02-15 | 2021-12-20 | Kanagawa Prefectural Hospital Organization | Rozpoznawanie białka typu błonowego podobnego do mucyny i jego zastosowanie kliniczne |
| CA3016287A1 (en) | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
| JP7251981B2 (ja) | 2016-03-24 | 2023-04-04 | バイエル ファーマ アクチエンゲゼルシャフト | 酵素開裂基を有する細胞毒性活性剤のプロドラッグ |
| EP3443096B1 (en) | 2016-04-15 | 2023-03-01 | Novartis AG | Compositions and methods for selective expression of chimeric antigen receptors |
| KR20190014525A (ko) | 2016-05-27 | 2019-02-12 | 애브비 바이오테라퓨틱스 인크. | 면역 조절 단백질과 종양 항원을 결합하는 이중특이적 결합 단백질 |
| WO2017216028A1 (en) | 2016-06-15 | 2017-12-21 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
| BR112018076525A2 (pt) | 2016-06-20 | 2019-04-02 | F-Star Beta Limited | membros de ligação a lag-3 |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| EP3490590A2 (en) | 2016-08-01 | 2019-06-05 | Novartis AG | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
| WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| US20190218294A1 (en) | 2016-09-09 | 2019-07-18 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment |
| MX2019003899A (es) | 2016-10-07 | 2019-08-14 | Tcr2 Therapeutics Inc | Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion. |
| AU2017363311A1 (en) | 2016-11-22 | 2019-06-13 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| IL324632A (en) | 2016-12-01 | 2026-01-01 | Regeneron Pharma | Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging |
| KR102556826B1 (ko) | 2016-12-21 | 2023-07-18 | 바이엘 파마 악티엔게젤샤프트 | 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc) |
| CA3047491A1 (en) | 2016-12-21 | 2018-06-28 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| WO2018114804A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
| EP3574005B1 (en) | 2017-01-26 | 2021-12-15 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
| EP3638295A1 (en) | 2017-06-13 | 2020-04-22 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| JP6339283B1 (ja) | 2017-10-31 | 2018-06-06 | 国立大学法人 岡山大学 | Ｄｎａ、ポリペプチド、抗メソセリン抗体、腫瘍イメージング剤及び複合体 |
| WO2019105835A1 (en) | 2017-11-29 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib and anetumab ravtansine |
| JP7489316B2 (ja) | 2017-12-19 | 2024-05-23 | エフ－スター セラピューティクス リミテッド | Ｐｄ－ｌｉ抗原結合部位を有するｆｃ結合断片 |
| FI3730612T3 (fi) * | 2017-12-24 | 2026-04-30 | Noile Immune Biotech Inc | Immunokompetentti solu, joka ilmaisee erityisesti ihmisen mesoteliinin, il-7:n ja ccl19:n tunnistavan solukalvon molekyylin |
| KR20210018807A (ko) | 2018-04-27 | 2021-02-18 | 바이오젠 엠에이 인코포레이티드 | 인간-유래 항-(폴리-ga) 디펩타이드 반복 (dpr) 항체 |
| EP3784351A1 (en) | 2018-04-27 | 2021-03-03 | Novartis AG | Car t cell therapies with enhanced efficacy |
| EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| US20210123075A1 (en) | 2018-06-08 | 2021-04-29 | Novartis Ag | Compositions and methods for immunooncology |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| PL3820569T3 (pl) | 2018-07-12 | 2025-07-14 | Invox Pharma Limited | Cząsteczki przeciwciał, które wiążą PD-L1 oraz CD137 |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| AU2019301206B2 (en) | 2018-07-12 | 2025-10-30 | Invox Pharma Limited | Antibody molecules that bind CD137 and OX40 |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| CN109053882B (zh) * | 2018-08-28 | 2019-08-23 | 东莞市朋志生物科技有限公司 | 一种ns1蛋白的结合蛋白以及应用 |
| MX2021002225A (es) | 2018-08-30 | 2021-07-16 | Tcr2 Therapeutics Inc | Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion. |
| EP3897851A2 (en) | 2018-12-17 | 2021-10-27 | Revitope Limited | Twin immune cell engager |
| WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| BR112021015672A2 (pt) | 2019-02-15 | 2021-10-05 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos |
| ES3032659T3 (en) | 2019-02-15 | 2025-07-23 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| EP3938393A1 (en) * | 2019-03-14 | 2022-01-19 | MorphoSys AG | Antibodies targeting c5ar |
| WO2020187998A1 (en) | 2019-03-19 | 2020-09-24 | Fundació Privada Institut D'investigació Oncològica De Vall Hebron | Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer |
| WO2020234114A1 (en) | 2019-05-21 | 2020-11-26 | Bayer Aktiengesellschaft | A novel stable high concentration formulation for anetumab ravtansine |
| WO2021021825A1 (en) * | 2019-07-29 | 2021-02-04 | Fred Hutchinson Cancer Research Center | Methods and compositions for inducing notch signaling in tumor microenvironments |
| JP2023507323A (ja) | 2019-12-20 | 2023-02-22 | アムジエン・インコーポレーテツド | 固形腫瘍の治療のためのメソセリン標的化ｃｄ４０アゴニスト多重特異性抗体コンストラクト |
| KR20220116257A (ko) | 2019-12-20 | 2022-08-22 | 노파르티스 아게 | 골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물 |
| CN115515976A (zh) * | 2020-03-19 | 2022-12-23 | 帝国理工学院创新有限公司 | 冠状病毒抗体 |
| CN116096862A (zh) | 2020-06-11 | 2023-05-09 | 诺华股份有限公司 | Zbtb32抑制剂及其用途 |
| CN115916199A (zh) | 2020-06-23 | 2023-04-04 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案 |
| US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| CN116063527A (zh) * | 2021-09-30 | 2023-05-05 | 南京北恒生物科技有限公司 | 靶向间皮素的抗体及其用途 |
| TW202321296A (zh) | 2021-10-06 | 2023-06-01 | 美商鏈接免疫療法公司 | 抗間皮素抗原結合分子及其用途 |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| CN120129696A (zh) | 2022-09-01 | 2025-06-10 | 乔治亚大学研究基金公司 | 用于指导载脂蛋白l1诱导哺乳动物细胞死亡的组合物和方法 |
| AU2023370106A1 (en) | 2022-10-25 | 2025-05-08 | Fundació Privada Institut D'investigació Oncològica De Vall Hebron | Combination therapy for the treatment of cancer |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| CN116019939A (zh) * | 2022-11-24 | 2023-04-28 | 华中科技大学同济医学院附属协和医院 | 靶向msln的分子探针以及用途 |
| EP4626930A2 (en) * | 2022-12-02 | 2025-10-08 | Jecho Laboratories, Inc. | Anti-mesothelin bispecific antibodies and methods of use |
| EP4701654A2 (en) | 2023-04-25 | 2026-03-04 | Arsenal Biosciences, Inc. | Novel receptors for transcription regulation |
| EP4720059A1 (en) | 2023-05-24 | 2026-04-08 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| EP4473974A1 (en) | 2023-06-07 | 2024-12-11 | Peptomyc, S.L. | Omomyc and kras inhibitors combination therapy for the treatment of cancer |
| WO2024251846A1 (en) | 2023-06-07 | 2024-12-12 | Fundació Privada Institut D'investigació Oncològica De Vall Hebron | Combination therapy with mek inhibitors for the treatment of cancer |
| KR20260020418A (ko) | 2023-06-07 | 2026-02-11 | 펀다시오 프리바다 인스티튜트 드인베스티가시오 온콜로지카 데 발 헤브론 | Braf 저해제를 이용한 암 치료용 조합 요법 |
| CN117659133B (zh) * | 2023-12-06 | 2024-09-20 | 南京鼓楼医院 | 间皮素靶向结合蛋白、其编码核酸以及用途 |
| CN117843793B (zh) * | 2024-03-07 | 2024-07-09 | 深圳真实生物医药科技有限公司 | 抗间皮素抗体、抗原结合片段及其用途 |
| WO2025235862A1 (en) | 2024-05-10 | 2025-11-13 | Inndura Therapeutics Inc. | A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a |
| WO2026089759A1 (en) | 2024-10-21 | 2026-04-30 | Sonnet BioTherapeutics, Inc. | Docking peptides and related antibody-based drug conjugates |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US6180377B1 (en) * | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| ATE219517T1 (de) | 1995-08-18 | 2002-07-15 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
| JP2000505787A (ja) * | 1996-01-05 | 2000-05-16 | アメリカ合衆国 | 中皮抗原及びそれを標的化するための方法及びキット |
| US6809184B1 (en) * | 1997-12-01 | 2004-10-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
| ES2255194T3 (es) * | 1997-12-01 | 2006-06-16 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Anticuerpos, que incluyen moleculas fv, e inmunoconjugados que presentan una afinidad de enlace elevada para la mesotelina y metodos para su utilizacion. |
| AU3007200A (en) * | 1999-02-26 | 2000-09-14 | Pacific Northwest Research Institute | Methods and compositions for diagnosing carcinomas |
| EP1990409A3 (en) | 1999-07-20 | 2011-05-18 | MorphoSys AG | Bacteriophage |
| EP2322560B1 (en) * | 2005-03-10 | 2013-09-04 | Morphotek, Inc. | Anti-mesothelin antibodies |
| WO2006124641A2 (en) * | 2005-05-12 | 2006-11-23 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health | Anti-mesothelin antibodies useful for immunological assays |
| NZ564027A (en) | 2005-05-18 | 2011-06-30 | Morphosys Ag | Anti-GM-CSF antibodies and uses therefor |
| KR20080031001A (ko) * | 2005-06-02 | 2008-04-07 | 아스트라제네카 아베 | Ｃｄ20에 대한 항체 및 그의 용도 |
| SI2195017T1 (sl) * | 2007-10-01 | 2015-01-30 | Bristol-Myers Squibb Company | Človeška protitelesa, ki vežejo mezotelin in njihova uporaba |
| HUE027358T2 (en) * | 2007-11-26 | 2016-09-28 | Bayer Ip Gmbh | Anti-mesothelin antibodies and their applications |
-
2008
- 2008-11-19 HU HUE08855189A patent/HUE027358T2/en unknown
- 2008-11-19 US US12/744,849 patent/US9023351B2/en active Active
- 2008-11-19 CN CN200880125390.8A patent/CN101952319B/zh not_active Expired - Fee Related
- 2008-11-19 HR HRP20160485TT patent/HRP20160485T1/hr unknown
- 2008-11-19 KR KR1020107011375A patent/KR101559599B1/ko not_active Expired - Fee Related
- 2008-11-19 CA CA2706529A patent/CA2706529C/en active Active
- 2008-11-19 EP EP08855189.0A patent/EP2215121B1/en active Active
- 2008-11-19 MX MX2010005603A patent/MX2010005603A/es active IP Right Grant
- 2008-11-19 EP EP13168583.6A patent/EP2634196A1/en not_active Ceased
- 2008-11-19 SI SI200831603A patent/SI2215121T1/sl unknown
- 2008-11-19 PL PL08855189T patent/PL2215121T3/pl unknown
- 2008-11-19 MY MYPI2010002379A patent/MY157164A/en unknown
- 2008-11-19 UA UAA201008006A patent/UA106036C2/uk unknown
- 2008-11-19 EP EP16170412.7A patent/EP3103814A1/en not_active Withdrawn
- 2008-11-19 DK DK08855189.0T patent/DK2215121T3/en active
- 2008-11-19 NZ NZ585551A patent/NZ585551A/en not_active IP Right Cessation
- 2008-11-19 CN CN201410396441.8A patent/CN104151429B/zh not_active Expired - Fee Related
- 2008-11-19 AU AU2008329221A patent/AU2008329221B2/en not_active Ceased
- 2008-11-19 WO PCT/EP2008/009756 patent/WO2009068204A1/en not_active Ceased
- 2008-11-19 JP JP2010535269A patent/JP5608091B2/ja not_active Expired - Fee Related
- 2008-11-19 BR BRPI0819909A patent/BRPI0819909B8/pt not_active IP Right Cessation
- 2008-11-19 ES ES08855189.0T patent/ES2569513T3/es active Active
-
2010
- 2010-05-11 IL IL205681A patent/IL205681A0/en active IP Right Grant
- 2010-05-20 DO DO2010000150A patent/DOP2010000150A/es unknown
- 2010-05-20 GT GT201000148A patent/GT201000148A/es unknown
- 2010-05-21 CR CR11456A patent/CR11456A/es unknown
- 2010-05-21 CO CO10061059A patent/CO6280409A2/es not_active Application Discontinuation
- 2010-05-21 CU CU2010000098A patent/CU23833A3/es active IP Right Grant
- 2010-05-21 EC EC2010010191A patent/ECSP10010191A/es unknown
- 2010-05-21 HN HN2010001062A patent/HN2010001062A/es unknown
- 2010-05-24 MA MA32865A patent/MA31862B1/fr unknown
- 2010-05-25 TN TN2010000234A patent/TN2010000234A1/fr unknown
-
2014
- 2014-07-03 JP JP2014137893A patent/JP2014221064A/ja active Pending
-
2015
- 2015-03-11 US US14/645,411 patent/US20150259433A1/en not_active Abandoned
-
2016
- 2016-04-27 CY CY20161100353T patent/CY1117437T1/el unknown
-
2018
- 2018-03-05 US US15/911,748 patent/US20180258181A1/en not_active Abandoned
- 2018-03-05 JP JP2018038254A patent/JP6717869B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR105026A1 (es) | ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO | |
| JP2019528038A5 (enExample) | ||
| JP2013538057A5 (enExample) | ||
| PH12018502623A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| JP2016516400A5 (enExample) | ||
| JP2018536393A5 (enExample) | ||
| NZ743713A (en) | Human immunodeficiency virus neutralizing antibodies | |
| IL265541B1 (en) | Bispecific antibodies and compositions comprising thereof for treating cancer | |
| JP2012143232A5 (enExample) | ||
| JP2018023398A5 (enExample) | ||
| PH12020551173A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| HK1252998A1 (zh) | Prame肽专一性类t细胞受体抗体 | |
| WO2018057735A8 (en) | Antibodies for siglec-15 and methods of use thereof | |
| JP2014526898A5 (enExample) | ||
| FI3237005T3 (fi) | Bispesifisiä tetravalentteja vasta-aineita sekä menetelmiä niiden valmistamiseksi ja käyttämiseksi | |
| JP2018504105A5 (enExample) | ||
| WO2016207304A8 (en) | Monoclonal anti-il-1racp antibodies | |
| HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
| EA201791666A1 (ru) | Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123 | |
| JP2018505681A5 (enExample) | ||
| JP2019523651A5 (enExample) | ||
| RU2017113732A (ru) | Антитело, которое обладает способностью нейтрализовать субстанцию, обладающую активностью, альтернативной функции фактора свертывания viii (fviii) | |
| FI3826667T3 (fi) | Claudin6 vasta-aineita ja menetelmiä syövän hoitamiseksi | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| RU2015126533A (ru) | Анти-cd47 антитела и способы их применения |